Psychedelic Business Spotlight – April 15

,
This week in psychedelic business news: The industry's first major merger; NeonMind launches clinics; a portfolio of patents is acquired.

Why Investors Should Care About MindMed’s LSD Trial for Anxiety

MindMed will present preliminary results from a Phase 2a study treating Generalized Anxiety Disorder with LSD therapy next month.

Numinus Acquires Novamind: What Does This Mean for the Psychedelic Industry? | NUMI, NM

Numinus Acquiring Novamind in First Major Psychedelics Merger Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20 Not only will this be your chance to meet me, but also the legendary Paul Stamets! Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc... Follow us on Twitter: James: @Psy_Invest Maria: @psy_holy The Psychedelic Investor: @PsycInvestor Psychedelic Spotlight: @PsycSpotlight Follow us on Instagram: @thepsychedelicinvestor @psycspotlight To learn more about the emerging psychedelic industry, visit: https://psychedelicspotlight.com/ Back to Numinus This acquisition will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability. Psychedelic stock investors woke up to some major news today: Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) announced that they are acquiring Novamind Inc. (CSE: NM) (OTCQB: NVMDF). The acquisition will be done in stock, and shareholders of Novamind will receive 0.84 of a common share of Numinus per Novamind share held, implying an offer price of $0.44 per Novamind share. This means Numinus is offering a premium of 51% to Novamind shareholders, based on the 20-day volume-weighted average price of their stock. When the transaction is completed, Novamind shareholders will own around 18% of Numinus. If you currently hold Novamind stock, you do not need to do anything. When the transaction is finalized, each Novamind share you own will automatically be transformed into 0.84 of a Numinus share. #Numinus #NovaMind #psychedelicStocks
Numinus Acquiring Novamind in First Major Psychedelics MergerShutterstock

Numinus Acquiring Novamind in First Major Psychedelics Merger

,
This deal will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.
Psychedelic Business Spotlight - April 8

Psychedelic Business Spotlight – April 8

,
This week in psychedelic business news: Field Trip Health secures a patent; Core One Labs seeks more retail investors; a new CEO takes over GABA Therapeutics.
Attend Canada’s Premiere Psychedelics Conference From Anywhere in the WorldShutterstock

Attend Canada’s Premiere Psychedelics Conference From Anywhere in the World

The 3rd annual Psychedelics Catalyst Summit at Queen’s University in Kingston, Ontario, will be available to live stream.

How to Legally Access Psychedelic Therapy in Canada | The Psychedelic Investor

How can someone legally access psychedelic therapy in Canada? This is the question that I ask David Harder, Founder and Co-CEO of ATMA. Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20 Not only will this be your chance to meet me, but also the legendary Paul Stamets! Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc... Follow us on Twitter: James: @Psy_Invest Maria: @psy_holy The Psychedelic Investor: @PsycInvestor Psychedelic Spotlight: @PsycSpotlight Follow us on Instagram: @thepsychedelicinvestor @psycspotlight To learn more about the emerging psychedelic industry, visit: https://psychedelicspotlight.com/ By now, most people watching this video are probably aware of the potential for psychedelic medicines, when combined with therapy, such as psilocybin and MDMA to treat a variety of mental health conditions. But receiving this treatment is still difficult. In Canada, in addition to clinical trials, there are a couple of avenues that a patient can go through to receive psychedelic therapy. The first is called the Section 56 exemption, which has allowed dozens of people suffering from anxiety relating to terminal illnesses to undergo psilocybin therapy. There is also a new avenue called the Health Canada "Special Access Program", though relatively few people have gone through that route so far. In the interview, we also discuss David's company, ATMA. ATMA is a company that trains therapists to conduct psychedelic therapies. They also conduct therapy themselves. Lastly, we discuss the upcoming Catalyst Psychedelic conference, happening in Kingston, Ontario between May 20-23rd. I will be there, and I hope to see you also!

Psychedelic Business Spotlight – April 1

,
This week in psychedelic business news: TripSitter expands; Enveric files a major patent; and Psychedelic Water raises its profile.

MindMed 2021 Year-End Conference Call and Earnings: Big Updates for MNMD Stock

MindMed 2021 Year-End Conference Call and Earnings: Big Updates for MNMD Stock Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psychedelic-news/industry/ All Psychedelic Stock investors should take the time to listen to the conference calls of the companies they are investing in. That is doubly important for year-end calls, as often information is divulged on the direction of the company. If you are invested in MNMD or MMED stock, you need to listen to this call. Follow us on Twitter: The Psychedelic Investor: @psycInvestor James: @Psy_Invest Maria: @psy_holy Psychedelic Spotlight: @PsycSpotlight Follow us on Instagram: @thepsychedelicinvestor @psycspotlight To learn more about the emerging psychedelic industry, visit: https://psychedelicspotlight.com/ Meet Kevin O'Leary, Rober Barrow, Daniel Carcillo and other psychedelic leaders @ the Benzinga Psychedelics Capital Conference.on April 19 @ Fontainebleau Hotel, Miami! https://www.eventbrite.com/e/benzinga-psychedelics-capital-conference-spring-2022-tickets-238697028237?discount=PSYCHSPOTLIGHT15&fbclid=IwAR3tJFhoVfVWZvAyQuWSLEo3kJSmaq8VGnQQPz04NMhG3g7rHtSmRSAUq64 COUPON CODE: PSYCHSPOTLIGHT15 Interested in going to Malta for Plant Medicine Week April 5th-8th? Get discounted tickets here: https://tickets.plantmedicineweek.com/attendance/event/index/41436/EN?promocodes=PSYC In this MindMed 2021 conference and earnings call, we gained important insights into the company’s many projects. These include: Project Lucy, which attempts to treat Anxiety using LSD; Project Angie, attempting to treat pain with LSD; Project Layla, attempting to treat addiction with 18-MC, and much more. The company gives some updates on the science of psychedelics, as well as their hiring strategy and financial updates. MindMed is a company working on treating mental health conditions with psychedelics. They are a leading player in the shroom boom, and they aim to commercialize psychedelics as medicines. Some of the questions MindMed is trying to answer are: Can Psychedelics treat Mental Health conditions? Can Psychedelics treat depression? Can Psychedelics treat anxiety? Can Psychedelics treat ADHD? Can Psychedelics help with Autism? Can Psychedelics help treat pain? #MindMed #MNMD #MindMedStocks
Interested in Psychedelic Stocks? This Is the BEST Resource for YouShutterstock

Interested in Psychedelic Stocks? This Is the BEST Resource for You

Introducing the Benzinga Psychedelics Capital Conference on April 19 in Miami Beach,